Lv3
370 积分 2026-01-28 加入
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
3天前
已完结
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
13天前
已完结
MA02.07 Efficacy and Safety of GFH375 in Advanced Non-small Cell Lung Cancer Patients with KRAS G12D Mutation
1个月前
已完结
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
2个月前
已完结
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
2个月前
已完结
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
2个月前
已完结
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
2个月前
已完结
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
2个月前
已完结
Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management
2个月前
已完结
Teclistamab in Relapsed or Refractory Multiple Myeloma
2个月前
已完结
皖公网安备34019202002308
